Current understanding of primary biliary cholangitis
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Primary biliary cholangitis (PBC) causes chronic and persistent cholestasis in the liver, eventually resulting in cirrhosis and hepatic failure without appropriate treatment. PBC mainly develops in middle-aged women, but it is also common in young women and men. PBC is considered a model of autoimmune disease because of the presence of diseasespecific autoantibodies, that is, antimitochondrial antibodies (AMAs), intense infiltration of mononuclear cells into the bile ducts, and a high prevalence of autoimmune diseases such as comorbidities. Histologically, PBC is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells surrounded by a dense infiltration of mononuclear cells, coined as chronic non-suppurative destructive cholangitis, which leads to destructive changes and the disappearance of small- or medium-sized bile ducts. Since 1990, early diagnosis with the detection of AMAs and introduction of ursodeoxycholic acid as first-line treatment has greatly altered the clinical course of PBC, and liver transplantation-free survival of patients with PBC is now comparable to that of the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“Among those patients, 46–47% achieved the primary end point.(98) Consequently, OCA received accelerated approval from the United States Food and Drug Administration (FDA) approval on May 27, 2016.”
BackgroundLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 3×
“A diagnosis of PBC is made when 2 or 3 following items are met: the 1) consistent elevation of cholestatic enzymes, 2) detection of AMA, and 3) typical liver histology.(58,68,69) Figure 2 shows a diagnostic flowchart.”
BackgroundParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
The International IBD Genetics Consortium (IIBDGC), Ellinghaus, D., International Genetics of Ankylosing Spondylitis Consortium (IGAS), International PSC Study Group (IPSCSG), Genetic Analysis of Psoriasis Consortium (GAPC), Psoriasis Association Genetics Extension (PAGE), Jostins, L., Spain, S. L., Cortes, A., Bethune, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3528 · Cited by 751
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.789 · Cited by 464
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Tang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., Yang, F., Miao, Q., Xiao, X., Zhang, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313332 · Cited by 434 · cited 3×
“Since the first report demonstrating its efficacy for PBC,(83) UDCA has dramatically altered the natural course of PBC and has been approved as a first-line therapy for PBC worldwide.(58,69,84) UDCA is used at a dose of 13–15 mg/kg/day, and is recommended for all patients with PBC with elevated liver biochemistry leve…”
BackgroundLysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
Liu, X., Invernizzi, P., Lu, Y., Kosoy, R., Lu, Y., Bianchi, I., Podda, M., Xu, C., Xie, G., Macciardi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.627 · Cited by 398
The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2616 · Cited by 391
Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics · doi:10.1038/ng.3745 · Cited by 357
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology · doi:10.1002/hep.25748 · Cited by 291
Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.001 · Cited by 289 · cited 7×
“Bezafibrate was first reported as biologically effective for patients with PBC who were refractory to UDCA in 1999.103 A prospective, randomized, placebo-controlled study of bezafibrate in PBC patients with incomplete responses to UDCA from France demonstrated that an add-on of bezafibrate to UDCA for 2 years signific…”
BackgroundResultInfluentialCordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9019 · Cited by 287
Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
Singal, A. K., Guturu, P., Hmoud, B., Kuo, Y.-F., Salameh, H., & Wiesner, R. H. (2013) · Transplantation · doi:10.1097/tp.0b013e31827afb3a · Cited by 278
Nakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., Nakamura, H., Komori, A., Nakamuta, M., Zeniya, M., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.08.010 · Cited by 267
Self-citationImpact of fatigue on the quality of life of patients with primary biliary cirrhosis
Huet, P.-M., Deslauriers, J., Tran, A., Faucher, C., & Charbonneau, J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01857.x · Cited by 262
Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis
Corpechot, C., Chrétien, Y., Chazouillères, O., & Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.019 · Cited by 235
Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study
Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology · doi:10.1002/hep.26365 · Cited by 227
Pruritus in cholestasis: facts and fiction
Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology · doi:10.1002/hep.26909 · Cited by 225 · cited 1×
“The cause of pruritus remains unknown, although several substances are hypothesized to be related to pruritus in cholestatic liver diseases.(141) Most notably, lysophosphatidic acid (LPA) may be a potential candidate for initiating pruritus,(142) and the activity of serum autotaxin, which converts lysophosphatidylchol…”
BackgroundNakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., Sano, K., Kondo, F., Fukusato, T., Tsuneyama, K., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2009.02500.x · Cited by 224 · cited 1×
“proposed a new histological staging and grading system for PBC (Tables 2-4).(81) In Nakanuma’s classification, the scores for fibrosis, bile duct loss, and deposition of orcein-positive granules were used for staging, whereas CA and HA were used for grading.”
MethodIncreased prevalence of primary biliary cirrhosis near Superfund toxic waste sites
Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222
Apotopes and the biliary specificity of primary biliary cirrhosis†
Lleo, A., Selmi, C., Invernizzi, P., Podda, M., Coppel, R. L., Mackay, I. R., Gores, G. J., Ansari, A. A., Van de Water, J., & Gershwin, M. E. (2009) · Hepatology · doi:10.1002/hep.22736 · Cited by 222 · cited 1×
“The hypothesis to solve this enigma is that human intrahepatic BECs could maintain PDC-E2 immunologically intact within apoptotic blebs (apotopes) during apoptosis.(33) Interestingly, a unique triad consisting of BEC apotopes, macrophages from patients with PBC, and AMAs could lead to rigorous production of inflammato…”
BackgroundVariants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis
Hirschfield, G. M., Liu, X., Han, Y., Gorlov, I. P., Lu, Y., Xu, C., Lu, Y., Chen, W., Juran, B. D., Coltescu, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.631 · Cited by 215
Bacteriuria and primary biliary cirrhosis.
Burroughs, A. K., Rosenstein, I. J., Epstein, O., Hamilton-Miller, J. M., Brumfitt, W., & Sherlock, S. (1984) · Gut · doi:10.1136/gut.25.2.133 · Cited by 214
Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30319-7 · Cited by 206 · cited 1×
“As an emerging novel therapy, an ileal bile acid transporter (IBAT) inhibitor compound (linerixibat) that inhibits reabsorption of bile acids in the ileum effectively decreased pruritus in patients with PBC in a phase 2a study.(148) A global phase 2b study (clinical trial ID: NCT02966834) investigating the efficacy of…”
BackgroundExtrahepatic autoimmune conditions associated with primary biliary cirrhosis
Floreani, A., Franceschet, I., Cazzagon, N., Spinazzè, A., Buja, A., Furlan, P., Baldo, V., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8427-x · Cited by 188
Amano, K., Leung, P. S. C., Rieger, R., Quan, C., Wang, X., Marik, J., Suen, Y. F., Kurth, M. J., Nantz, M. H., Ansari, A. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5874 · Cited by 187
Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis
Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P. M., Podda, M., Mackay, I. R., Gershwin, M. E., & Invernizzi, P. (2016) · Scientific Reports · doi:10.1038/srep25906 · Cited by 186 · cited 1×
“1:1.(19) The reason for the relative increase in the number of male patients with PBC remains unclear, but a better recognition and a true increase in the incidence of PBC are likely responsible.”
BackgroundTrauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30094-9 · Cited by 180
Charatcharoenwitthaya, P., Pimentel, S., Talwalkar, J. A., Enders, F. T., Lindor, K. D., Krom, R. A. F., & Wiesner, R. H. (2007) · Liver Transplantation · doi:10.1002/lt.21124 · Cited by 179
Guañabens, N., Parés, A., Ros, I., Caballería, L., Pons, F., Vidal, S., Monegal, A., Peris, P., & Rodés, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.035 · Cited by 179
Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308351 · Cited by 178 · cited 2×
“0001).(160) Taken together, close monitoring of HCC is strongly recommended for high-risk patients with PBC, such as male patients, those with advanced-stage disease, and non-responders to UDCA.”
BackgroundTandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176 · cited 2×
“In daily clinical practice, anion-exchange resins such as cholestyramine, rifampsin, and opiate antagonists are used.(145) Anion-exchange resins are recommended as the first-line therapy in the American Association for the Study of Liver Diseases and European Association for the Study of the Liver guidelines, despite…”
BackgroundCarbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30163-8 · Cited by 155
Neuberger, J., Gunson, B., Hubscher, S., & Nightingale, P. (2004) · Liver Transplantation · doi:10.1002/lt.20123 · Cited by 155
Juran, B. D., Hirschfield, G. M., Invernizzi, P., Atkinson, E. J., Li, Y., Xie, G., Kosoy, R., Ransom, M., Sun, Y., Bianchi, I., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds359 · Cited by 150
Sylvestre, P. B., Batts, K. P., Burgart, L. J., Poterucha, J. J., & Wiesner, R. H. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50213 · Cited by 148
Characterization of antimitochondrial antibodies in healthy adults
Mattalia, A., Quaranta, S., Leung, P. S. C., Bauducci, M., Van de Water, J., Calvo, P. L., Danielle, F., Rizzetto, M., Ansari, A., Coppel, R. L., et al. (1998) · Hepatology · doi:10.1002/hep.510270303 · Cited by 146 · cited 1×
“AMAs are occasionally detected in less than 1% of healthy individuals with normal liver test results.(72,73) Individuals who are AMA-positive are at higher risk of developing PBC and require close follow-up, although the risk does not appear to be high, as previously believed.”
BackgroundGuañabens, N., Cerdá, D., Monegal, A., Pons, F., Caballería, L., Peris, P., & Parés, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.016 · Cited by 142
A genome-wide association study identifies six novel risk loci for primary biliary cholangitis
Qiu, F., Tang, R., Zuo, X., Shi, X., Wei, Y., Zheng, X., Dai, Y., Gong, Y., Wang, L., Xu, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms14828 · Cited by 140
Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
Dahlqvist, G., Gaouar, F., Carrat, F., Meurisse, S., Chazouillères, O., Poupon, R., Johanet, C., & Corpechot, C. (2017) · Hepatology · doi:10.1002/hep.28859 · Cited by 137 · cited 1×
“1 per 100,000 population, and one in six patients with AMA positivity and a normal ALP level developed PBC within 5 years.(74) Conversely, a recent study from China demonstrated that more than 80% of patients with AMA without elevation of serum ALP levels also developed histological characteristics of PBC, suggesting…”
BackgroundLiu, H., Norman, G. L., Shums, Z., Worman, H. J., Krawitt, E. L., Bizzaro, N., Vergani, D., Bogdanos, D. P., Dalekos, G. N., Milkiewicz, P., et al. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.09.005 · Cited by 130 · cited 1×
“7% for diagnosing PBC and was considered appropriate as the first-line screening test.(76) Molecular mimicry between mitochondrial antigens and sp100/gp210 was reported.”
BackgroundCarbone, M., Bufton, S., Monaco, A., Griffiths, L., Jones, D. E., & Neuberger, J. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.017 · Cited by 115 · cited 1×
“Fatigue may be improved by LT, but it can also persist in a substantial portion of patients even after LT, making the role of LT as a therapeutic option for severe fatigue questionable.(139) Modafinil, which is officially approved by the FDA for wakefulness disorders, has been used, but a recent randomized, placebo-co…”
BackgroundBosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.-Y., Wendum, D., Conti, F., Morard, I., Rubbia-Brandt, L., Terris, B., Radenne, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.038 · Cited by 114 · cited 5×
“Recently, two cohort studies from Japan demonstrated that the increased frequency of recurrent PBC is associated with initial treatment with cyclosporine after LT.117,122 Although it is believed that recurrence of PBC does not have a significant impact on long-term outcomes, such as overall survival,123,130 a recent s…”
BackgroundInfluentialCx3cl1 (Fractalkine): A Signpost for Biliary Inflammation in Primary Biliary Cirrhosis
Shimoda, S., Harada, K., Niiro, H., Taketomi, A., Maehara, Y., Tsuneyama, K., Kikuchi, K., Nakanuma, Y., Mackay, I. R., Gershwin, E. M., et al. (2010) · Hepatology · doi:10.1002/hep.23318 · Cited by 108
Guañabens, N., Monegal, A., Cerdá, D., Muxí, Á., Gifre, L., Peris, P., & Parés, A. (2013) · Hepatology · doi:10.1002/hep.26466 · Cited by 99
Cyclosporine A Protects Against Primary Biliary Cirrhosis Recurrence After Liver Transplantation
Montano, A. J., Wasilenko, S., Bintner, J., & Mason, A. L. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03006.x · Cited by 99
Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’
Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.031 · Cited by 97
Self-citationSamur, S., Klebanoff, M., Banken, R., Pratt, D. S., Chapman, R., Ollendorf, D. A., Loos, A. M., Corey, K., Hur, C., & Chhatwal, J. (2017) · Hepatology · doi:10.1002/hep.28932 · Cited by 89 · cited 1×
“Based on the high cost of OCA ($69,350 per year), its never-ending prescription places substantial economic burdens on patients and societies; thus, it is not cost-effective.(99) Finally, it has not yet been confirmed whether the primary end points (ALP level <1.”
BackgroundHegade, V. S., Khanna, A., Walker, L. J., Wong, L.-L., Dyson, J. K., & Jones, D. E. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4250-y · Cited by 86 · cited 1×
“Fenofibrate was reported to decrease serum ALP levels in studies from Japan and China,(107,108) whereas the adjunct use of fenofibrate with UDCA showed no association with decreased serum ALP levels in a United Kingdom study.(109) Participants were recruited for a prospective randomized study in China (clinical trial…”
BackgroundHirschfield, G. M., Xie, G., Lu, E., Sun, Y., Juran, B. D., Chellappa, V, Coltescu, C., Mason, A. L., Milkiewicz, P., Myers, R. P., et al. (2012) · Genes & Immunity · doi:10.1038/gene.2011.89 · Cited by 85
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Momah, N., Silveira, M. G., Jorgensen, R., Sinakos, E., & Lindor, K. D. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02678.x · Cited by 77
Silveira, M. G., Gossard, A. A., Stahler, A. C., Jorgensen, R. A., Petz, J. L., Ali, A. H., & Lindor, K. D. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000387 · Cited by 64
McNally, R. J. Q., James, P. W., Ducker, S., Norman, P. D., & James, O. F. W. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwt308 · Cited by 62
Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population
Dong, M., Li, J., Tang, R., Zhu, P., Qiu, F., Wang, C., Qiu, J., Wang, L., Dai, Y., Xu, P., et al. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8472-0 · Cited by 54
Kawashima, M., Hitomi, Y., Aiba, Y., Nishida, N., Kojima, K., Kawai, Y., Nakamura, H., Tanaka, A., Zeniya, M., Hashimoto, E., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddw406 · Cited by 52
Self-citationHarada, K., Hsu, M., Ikeda, H., Zeniya, M., & Nakanuma, Y. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31827234e4 · Cited by 46 · cited 1×
“Overall survival was stratified better with Nakanuma’s classification than with the classic system.(82) TREATMENT”
MethodChanging nomenclature for PBC: From 'cirrhosis' to 'cholangitis'
Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.08.001 · Cited by 43
Self-citationYagi, M., Matsumoto, K., Komori, A., Abe, M., Hashimoto, N., Inao, M., Namisaki, T., Kawata, K., Ninomiya, M., Fujii, H., et al. (2020) · Liver International · doi:10.1111/liv.14534 · Cited by 20 · cited 1×
“Very recently, the validity of the UDCA response score was demonstrated in a Japanere cohort.(97)”
BackgroundSelf-citation
Cited by
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants
Yang, Y., Choi, J., Chen, Y., Invernizzi, P., Yang, G., Zhang, W., Shao, T., Jordan, F., Nemeria, N. S., Coppel, R. L., et al. (2022) · Hepatology · doi:10.1002/hep.32172 · Cited by 44
Metadata
- Authors
- Tanaka, A.
- Venue
- Clinical and Molecular Hepatology
- Published
- 2021-01-01
- Volume
- 27
- Issue
- 1
- Pages
- 1-21
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- OpenAlex
- W3108976510
- Cited by
- 158
- References
- 74
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.